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Abstract
Pain, sifness of joints, and funcional disability of rheumatoid arthriis (RA) are maximum 
in the morning. Cytokines, especially interleukin (IL)‑6, demonstrate a circadian variaion in 
paients with RA and contribute to the severity of aforemenioned symptoms. Perturbed 
corisol response in paients with RA is not efecively able to negate the efects of interleukin 
6 rise in the early morning. Modiied‑release (MR) prednisone is a polymer‑based drug delivery 
system which releases the drug 4 h ater the ingesion of tablet closely simulaing the corisol 
rise and peak in paients with RA. In this review, we focus on the raionale for chronotherapy, 
mechanisic consideraions, and clinical implicaions of MR prednisone.
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Introducion
Rheumatoid arthriis (RA) is a chronic systemic autoimmune 
inlammatory disease which is associated with progressive 
disability, poor quality of life, and systemic complicaions. 
Glucocoricoids (GCs) with their muliple mechanisms 
of acion are an efecive tool to treat RA.[1,2] Available 
evidence also underscores their disease‑modifying efect 
on the structural damage in RA without any convincing 
toxicity when used in low doses.[3,4] Three factors, namely, 
GC resistance, concerns regarding toxicity of GC, and 
unproven superiority and safety of GC molecules such as 
Delazacort, coninue to drive the quest to develop GCs 
with beter risk–beneit raio.[1,5,6] Novel GCs that induce 
transrepression but simulate litle or no transacivaion 
are invesigated. In addiion, novel drug delivery systems 
and combinaions are also being developed. In this review, 
we appraise a novel drug delivery system of prednisone, 
i.e., modiied‑release (MR) prednisone.
Circadian Rhythms in Rheumatoid Arthriis
Various diurnal variaions or circadian rhythms of the human 
body are rooted to the suprachiasmaic nucleus (SCN) in 
the hypothalamic region of the brain. Sleep‑wake cycle, 
body temperature, heart rate, blood pressure, hormone 
regulaion, and immunity are the physiological funcions 
that fall under the purview of circadian control.[7] The SCN 
and paraventricular nucleus modulate circadian rhythms 
in the sympatheic and parasympatheic neurons, thereby 
inluencing diurnal variaions in gene transcripion in 
diferent lymphoid issues (which regulate the immune 
system) through posiive modulators (CLOCK; circadian 
locomotor output cycles kaput and BMAL1; brain and 
muscle aryl hydrocarbon receptor nuclear translocator 
like‑1) and negaive regulators (PER; period and CRY; 
cryptochrome).[8]
Reduced producion of corisol in the early morning 
and increased producion of melatonin in the night 
inluence the severity of early morning symptoms of 
RA.[9] The hypothalamic‑pituitary‑adrenal (HPA) axis and 
its associated circadian variaions in corisol (which can 
counter the efects of increased interleukin [IL‑6] levels) 
are also disturbed in RA.[10]
In one of the early studies, a diurnal variaion in the grip 
strength and joint sifness in RA was reported.[11] There 
was about 28% improvement in grip strength at 6.00 pm 
compared to 6.00 am and the joint sifness reduced by 
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40% at 6.00 pm compared to 6.00 am.[11] In another study, 
paients reported minimal grip strength and maximal joint 
swelling in the morning, while subjecive pain and sifness 
scores were also highest in the morning.[12] Alteraions in 
circadian rhythm of circulaing serum corisol, melatonin, 
and IL‑6 correlate with the hypofuncioning of the HPA axis 
in paients with RA.[13]
The corisol peak and nadir shited to earlier imes of the 
day in those paients with low erythrocyte sedimentaion 
rates (ESRs up to 40 mm/h) and medium disease acivity 
(ESR between 40 and 80 mm/h) in a study.[13] On the 
contrary, the circadian rhythm was lost or markedly reduced 
in paients with high acivity (i.e., those with >80 mm/h).[13] 
In another study, a signiicant correlaion was also noted 
between inlammatory acivity in RA and adrenal corisol 
secreion (coeicient of regression r = 0.63, n = 26, 
P < 0.001).[14]
IL‑6 is a potent acivator of the HPA axis as well as 
an important systemic mediator of the acute phase 
response in acive RA. In one study, IL‑6, ESR, and 
C‑reacive protein (CRP) signiicantly correlated with 
serum corisol, which is elevated in acive RA, depending 
on disease acivity.[15] In another study in comparison 
to normal subjects, plasma IL‑6 levels were signiicantly 
elevated in paients with RA with a circadian rhythm 
observed [Figure 1].[16]
Melatonin works on immune system by regulaing 
cytokine producion of immunocompetent cells. Melatonin 
simulates the producion of IL‑2, interferon γ, IL‑12, 
and IL‑6.[17] The concentraion of these cytokines peaks 
in the early morning, and at the same ime, the serum 
melatonin levels also peaks. In fact, the melatonin levels 
have been found to be signiicantly higher in paients with 
RA compared to controls. Although progressive increase 
in melatonin was observed in those with RA and control 
subjects from 8.00 pm up to 1st h of the morning, the peak 
serum melatonin concentraion was reached earlier by at 
least 2 h in RA paients than in control subjects (P < 0.05). 
The melatonin plateau was sustained for 2–3 h in RA 
paients but not in control subjects. Ater 2.00 pm, there 
was no diference in decrease of melatonin levels in both 
RA paients and control subjects.[18] Hence, the nocturnal 
melatonin rhythm is altered in paients with RA with 
earlier peak and a longer duraion in the early morning.
Prolacin is also thought to have a pathogenic role in 
RA.[19] The prolacin levels were found to be elevated in 
the serum as well as in the synovial luids in paients with 
RA.[20] A signiicant correlaion was found between high 
prolacin levels and the duraion of RA (r = 0.23; P = 0.01) 
as well as funcional stage (r = 0.24; P = 0.01).[21]
Chronotherapy with Glucocoricoids
Chronotherapy exploits the known disturbed circadian 
rhythms to opimize treatment outcomes and minimize 
adverse efects. Aforemenioned observaions suggest 
that the opimal ime for delivery of GC treatment is 
during the night, to mimic the normal circadian rhythm 
of corisol secreion and target the efects of nocturnal 
proinlammatory simuli. The iniial chronotherapies 
involving GCs were imed in the morning, which coincided 
with the commencement of diurnal acivity of RA 
symptoms.[22] A trial tested administraion of low‑dose 
prednisolone (5 or 7.5 mg daily) at 2.00 am which showed 
favorable efects on the duraion of morning sifness, joint 
pain, aricular indices, and morning serum concentraions 
of IL‑6 (P < 0.01).[22]
In the 1980’s, a unique twice‑a‑day GC combinaion 
chronotherapy (Duimelan 8–15™) was introduced to 
mimic the endogenous circadian corisol rhythm. The 8.00 
am tablet contained 7 mg prednisolone acetate plus 4 mg 
prednisolone alcohol and 3.00 pm tablet contained 3 mg 
prednisolone alcohol and 15 mg prednisolone acetate. As 
safe as the convenional GCs, it fell out of favor due to 
poor paient compliance.[23]
In a subsequent study, no diference in the circadian 
rhythms of inger joint swelling and of grip strength 
was noted when the GC was dosed at diferent imes 
Figure 1: Circadian rhythm of symptoms and interleukin‑6  (modiied from reference 16)
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(once‑daily at 8.00 am, 1.00 pm, or 11.00 pm).[24] However, 
in a diferent study, nighime dosing of low‑dose GCs 
signiicantly reduced the duraion of morning sifness 
when compared to morning‑ime once‑daily, driving home 
the point that the opimum ime of GC dosing is at night.[25]
Modiied‑release Prednisone
The main diference between MR prednisone and 
convenional/immediate‑release (IR) prednisone is the 
ime‑delayed release of the acive agent. Following oral 
ingesion (at 10.00 pm) of the MR tablet of prednisone, 
water penetrates the tablet as it passes through the 
gastrointesinal tract and the coaing bursts approximately 
4 h ater the ingesion and releases prednisone at about 
2.00 am.[26] This closely simulates the normal physiological 
rise of corisol which negates the IL‑6‑related early 
morning disease manifestaions of RA.
Clinical Eicacy of Modiied‑release Prednisone
a. Randomized controlled studies
Circadian Administraion of Prednisone in Rheumatoid 
Arthriis (CAPRA‑1) was a 12‑week, mulicenter, 
randomized, double‑blind trial which compared the 
eicacy of MR prednisone with that of IR prednisone 
in 288 paients with acive RA who were receiving 
stable doses of disease‑modifying anirheumaic drugs 
(DMARDs).[27] Their average daily duraion of morning 
sifness was 45 min or more.[27] 12 weeks of treatment 
with evening administraion of MR prednisone resulted 
in a substanially greater decrease in duraion of morning 
sifness of the joints than was recorded ater morning 
administraion of IR prednisone (relaive change; from 
baseline 164.1 [101.4] min vs. 182.5 [125.0] min to at 
the study end − 22.7% [89.1] min vs. −0.4% [89.0] min, 
P = 0.045).[27] At the end of treatment, paients in the 
prednisone MR group achieved a mean reducion of 
44 min in the morning sifness compared with baseline. 
This improvement in morning sifness with MR prednisone 
was already evident ater 2 weeks of treatment, with a 
diference of 10% between the two treatment groups. 
With coninued treatment, this diference increased and 
plateaued at around 38% from week 7 to the end of the 
12‑week treatment period. However, secondary outcomes 
for eicacy such as pain intensity during the day, quality 
of sleep, DAS28, physician’s global assessment of disease 
acivity, laboratory variables (ESR, CRP), and health 
assessment quesionnaire disability index did no difer 
between the two groups.[27]
CAPRA‑2 invesigated the eicacy and safety of 
low‑dose prednisone chronotherapy in paients with 
acive RA receiving standard DMARD treatment in a 
12‑week, double‑blind, randomized, parallel‑group, 
placebo‑controlled mulicenter study.[28] At week 12, 
48% of paients receiving MR prednisone achieved an 
ACR20 response, compared with 29% in the placebo 
group (P < 0.001).[28] The response was achieved 
rapidly: A signiicant diference in ACR20 response rate 
between treatment groups was evident at week 2, and 
the diference remained signiicant throughout the 
study (P < 0.005). ACR50 responder rates were numerically 
greater with MR prednisone than with placebo at all ime 
points, and the diference was signiicant at weeks 6 and 
12 (22% vs. 10% at week 12, P < 0.006).[28] Signiicantly 
greater decreases in the severity of morning sifness and 
recurrence of sifness later in the day were also seen for 
MR prednisone compared with placebo (P ≤ 0.01) as well 
as in the morning and evening pain.
b. Switching to  modiied‑release prednisone
Of paients with RA originally randomized to MR or 
IR prednisone, all eligible 249 paients received MR 
prednisone chronotherapy (2–10 mg/day) in the 9‑month 
open‑label extension of CAPRA‑1.[29] Irrespecive of 
whether paients were coninued on MR prednisone 
(MR/MR group) or switched from IR to MR prednisone 
(IR/MR group), there was sustained reducion in morning 
sifness. Ater 6 months of treatment, morning sifness 
was reduced in the IR/MR group by 54% and in the MR/MR 
group by 56%; morning sifness reducion ater 12 months 
was 45% in IR/MR group and 55% in MR/MR group.[29] 
DAS28 and pain showed clinically relevant improvements 
with no diferences between the treatment groups. Of 
the 219 paients who completed the enire study, 37% 
achieved an ACR20 response.[29]
In an open‑label observaional study, 950 RA outpaients 
who were treated with GCs and DMARDs were switched 
from IR prednisone or 6‑methyl (6M)‑prednisolone to 
low‑dose MR prednisone and followed for 4 months.[30] 
At 4 months, treatment with MR prednisone signiicantly 
decreased the duraion of morning sifness [Figure 2].[30] 
Switching over to MR prednisone signiicantly alleviated 
the intensity of pain as measured on numerical raing 
scale [Figure 3].[30] Paient and physician global assessment 
Figure 2: Switching over to modified‑release prednisone from either 
6‑methyl prednisone or immediate‑release prednisone resulted in signiicant 
reduction in morning stiffness (P < 0.001) (drawn from data in reference 30)
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scores of disease acivity also improved signiicantly from 
baseline (P < 0.001).[30]
Efect of modiied‑release prednisone on cytokines 
and hormones
In the CAPRA‑1 study, IL‑6 levels decreased in MR 
prednisone group but remained constant in the IR group 
(relaive reducion of nearly 29% vs. 0%).[27] In the long‑term 
extension of the CAPRA‑1 study, the same reducion by 
about 50% was seen at the end of the study in the IR/MR 
group.[29] Low levels of IL‑6 were sustained, but no further 
reducion was observed in the MR/MR group.[29] In CAPRA‑2 
study compared to placebo, the decrease in IL‑6 was greater 
in the MR prednisone group.[28] No change in the TNFα 
levels was observed between the two treatment arms.[28] 
In another study, the high pretreatment peak of IL‑6 was 
abolished following treatment with MR prednisone.[31] 
Moreover, the changes in IL‑6 correlated with the changes 
in morning sifness. There was a reducion in aternoon 
and evening serum corisol, but the early morning corisol 
peak concentraion increased.[31]
Safety and tolerability of modiied‑release 
prednisone
Treatment‑emergent adverse events (AEs) during the 
12‑week blinded period in CAPRA‑1 were not diferent 
between MR and IR prednisone groups.[27,32] In the 
long‑term extension of this study, the median duraion of 
exposure to MR prednisone was 281 days and the mean 
dose was 6.8 mg/day.[29] In CAPRA‑2 study, the overall 
incidence of AEs was slightly lower in paients receiving 
MR prednisone than in those receiving placebo, and 
none of the serious or severe AEs in the MR prednisone 
group was considered related to treatment.[28] In addiion, 
there was no evidence for an increased risk of infecion 
with acive treatment.[28] On analyzing the results of 
aforemenioned studies, overall, the safety and tolerability 
of MR prednisone appear similar to IR/convenional 
prednisone as reported in the literature.[2,4,33,34]
Efect of chronotherapy with modiied‑release 
prednisone on hypothalamic‑pituitary‑adrenal axis
Treatment with exogenous GCs afects the HPA; however, 
chronotherapy with MR prednisone had no AE on the 
HPA axis funcion.[27] In another study, over a period 
of 12 months, no deterioraion or onset of adrenal 
insuiciency was reported.[34] There was no diference in the 
mean corisol response between ime points [Figure 4].[35] In 
Figure 3: Switching over to modiied‑release prednisone from either 6‑methyl 
prednisone or immediate‑release prednisone signiicantly alleviated the 
intensity of pain after 4 months (P < 0.001)  (drawn from data in reference 30)
Figure 4: Maximum changes of cortisol after corticorelin injection in repeated tests of individual patients (modiied from reference 35). Time points “pre” 
and “zero” are before corticorelin injection. “Post” denotes highest value of the two assessments at 30 or 60 min after injection. (a) Repeated tests on 
unchanged immediate‑release prednisone. Pale orange indicates score after Test 1; dark orange after Test 2, n = 11. (b) Repeated tests on unchanged 
modiied‑release prednisone. Pale green indicates score after Test 2; dark green after Test 3, n = 7. (c) Results after the change of treatments from IR to 
MR prednisone after randomization. Pale blue: Test 1, MR/MR; dark blue: Test 2, after double‑blind MR, n = 7. (d) Repeated tests after change at end of 
double‑blind phase from IR to MR prednisone. Pale brown: Test 2 after double‑blind IR prednisone; dark brown: after 9 months of open MR prednisone, n = 9
dc
ba
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the long‑term extension of CAPRA‑1, no signs or symptoms 
were noted that might indicate aggravaion of suppression 
of the HPA axis.[29] Moreover, there was a 12% increase 
in maximum corisol response (from 12 weeks to 9 
months) in those who shited to MR prednisone ater 
being treated with IR prednisone for 12 weeks.[28,36] This 
suggests an improvement rather than deterioraion 
in the responsiveness of HPA axis in paients with RA 
receiving chronotherapy with MR prednisone compared to 
convenional morning prednisone treatment.[36]
Conclusion
Awareness of the associaion between altered circadian 
patern of cytokines and hormones, and disease acivity 
in RA has resulted in a new treatment paradigm; the 
chronotherapy with MR prednisone. Synchronizing the 
iming of GC therapy with the nocturnal increase in blood 
IL‑6 levels leads to alleviaion of pain and sifness far 
beter that a morning dose of convenional prednisone. 
MR formulaion of prednisone that is administered in the 
night at 10.00 pm is biologically available at 2.00 am, and 
this ime of release is ideal to counter the circadian rise 
in pro‑inlammatory cytokine levels. There is evidence 
from mechanisic studies that the increase in IL‑6 was 
indeed almost completely suppressed and HPA axis 
responsiveness was not suppressed and may even be 
enhanced by 2.00 am prednisone. Toxicity of this imed 
release is similar to convenional IR prednisone. A switch 
from IR/convenional prednisone to MR prednisone can be 
made and leads to improvement in troublesome morning 
sifness. MR prednisone therefore appears to be a useful 
addiion to the armamentarium used in the treatment of 
RA along with therapy with DMARDs.
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